Back to Stocks

VNDA

Vanda Pharmaceuticals Inc.
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Vanda Pharmaceuticals is approaching a pivotal transition as it evolves from a single-product dependency into a diversified commercial entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative surrounding new launches, Vanda's financial fundamentals reveal a company struggling with structural decline and escalating costs.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every VNDA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark contrast between operational momentum and financial instability. On one hand, the explosive growth of Fanapt and the successful regulatory clearance of BYSANTI and NEREUS provide a credible path toward revenue diversification. On the other, the accelerating quarterly net loss and the rapid depletion of cash reserves highlight the immense cost of these commercial transitions. Ultimately, Vanda's valuation now hinges on the execution of its new product launches. The company has successfully shifted its R&D focus and expanded its sales force, but the market remains skeptical of the burn rate required to sustain this growth. The upcoming months will determine if the direct-to-consumer model for NEREUS and the rollout of BYSANTI can offset the terminal decline of HETLIOZ and the widening operational losses.

Selected Quarter

Core Takeaway

Vanda is transitioning to a multi-launch commercial phase, but the cost of this transition is resulting in significantly wider quarterly losses.

Investor Lens

The trade-off is between the high-growth potential of a diversified pipeline and the immediate risk of capital exhaustion.

Watch Next

The PDUFA target date for imsidolimab on December 12, 2026, and initial revenue reports for NEREUS.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.27Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%
bearishMay 7

Net loss increased 65% year-over-year to $48.6 million.

earnings miss
70%
bearishMay 7

SG&A expenses surged 36% to fund commercial launches, outpacing revenue growth.

margin compression
60%
bullishMay 7

Successful transition to multi-product commercialization with NEREUS and BYSANTI.

acquisition
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a stark contrast between operational momentum and financial instability. On one hand, the explosive growth of Fanapt and the successful regulatory clearance of BYSANTI and NEREUS provide a credible path toward revenue diversification. On the other, the accelerating quarterly net loss and the rapid depletion of cash reserves highlight the immense cost of these commercial transitions. Ultimately, Vanda's valuation now hinges on the execution of its new product launches. The company has successfully shifted its R&D focus and expanded its sales force, but the market remains skeptical of the burn rate required to sustain this growth. The upcoming months will determine if the direct-to-consumer model for NEREUS and the rollout of BYSANTI can offset the terminal decline of HETLIOZ and the widening operational losses.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.